KRAS and lung carcinoma: Based on the mutation profiling of 363 lung adenocarcinoma patients, we present the first portrait of activating mutations present in the Indian lung cancer genome (Figure 1B), wherein 160 of 363 patients were found to harbor activating mutations across 8 genes at following frequency: EGFR (28.4%), KRAS (13%), ALK (3.8%), AKT1 (2.5%), PIK3CA (1.4%), FGFR4 (0.4%) and ERBB2 (0.3%) as shown in Figure 1A, consistent with earlier reports [6, 8, 9].